Clinomics Inc.

A352770

KR7352770002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
1,922 ^KRW	-3.90%		+5.55%	-25.07%

2023	Clinomics Inc. announced that it expects to receive KRW 15 billion in funding from Busan Equity Partners Co., Ltd.	CI
2023	Tranche Update on Clinomics Inc.'s Equity Buyback Plan announced on August 30, 2023.	CI

Clinomics Inc.(KOSDAQ:A352770) added to S&P Global BMI Index

June 21, 2021 at 12:00 am EDT

Latest news about Clinomics Inc.

Clinomics Inc. announced that it expects to receive KRW 15 billion in funding from Busan Equity Partners Co., Ltd.	Dec. 14	CI
Tranche Update on Clinomics Inc.'s Equity Buyback Plan announced on August 30, 2023.	23-08-30	CI
Clinomics Inc. announces an Equity Buyback for 124,764 shares.	23-08-30	CI
Clinomics Inc.'s Equity Buyback announced on August 30, 2023, has closed with 124,764 shares, representing 0.61% for KRW 299.43 million.	23-08-29	CI
Clinomics Inc. authorizes a Buyback Plan.	23-08-29	CI
Clinomics to Raise 44.6 Billion Won via Shares Issuance	23-05-22	MT
Clinomics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Clinomics Inc. announced that it expects to receive KRW 2.3 billion in funding	23-02-20	CI
Clinomics Inc. announced that it has received KRW 2.99999694 billion in funding	22-12-15	CI
Clinomics Inc. announced that it expects to receive KRW 2.99999694 billion in funding	22-11-30	CI
Clinomics Inc.(KOSDAQ:A352770) dropped from S&P Global BMI Index	22-09-19	CI
Clinomics Inc. announced that it has received KRW 30 billion in funding	21-07-06	CI
Clinomics Inc. announced that it expects to receive KRW 30 billion in funding	21-07-01	CI
Clinomics Inc.(KOSDAQ:A352770) added to S&P Global BMI Index	21-06-21	CI
Clinomics Inc. has completed an IPO in the amount of KRW 27.41529 billion.	20-11-26	CI
Clinomics Inc. has filed an IPO.	20-07-10	CI

Clinomics Inc is a Korea-based company engaged in the development of genome diagnostic tests and liquid biopsies. The Company's main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. It is also develops products that diagnoses cancer early with blood.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CLINOMICS INC.	-25.07%	45.83M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.23%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B